MariMed Names Howard Schacter as Chief Communications Officer

2.5 min readPublished On: June 2nd, 2021By
NORWOOD, Mass.,–MariMed, Inc. (OTCQX: MRMD), a multi-state cannabis operator focused on health and wellness, today announced Howard Schacter has been appointed as the Company’s Chief Communications Officer and a member of the MariMed Executive Management Team.
“I am thrilled to welcome Howard to the MariMed team and look forward to him significantly elevating visibility of the Company and our brand portfolio,” said Bob Fireman. “Howard’s unique background combines traditional corporate communications and brand marketing PR in cannabis, CPG, retail and other sectors. We are on a growth trajectory, with a focused strategic plan that’s working. Howard brings exactly the right skill set to tell our compelling MariMed story to investors and the media, to generate even more attention for our award-winning brands among customers and patients, and to align our employees around our mission and values.”

Mr. Schacter brings a wealth of communications experience to MariMed, having counseled companies including Facebook, McDonald’s, Microsoft, Spotify, and many others as a senior executive at leading PR agencies. He most recently served for three years as head of communications for another leading multi-state cannabis operator, Acreage Holdings. Prior to entering the cannabis industry, Mr. Schacter earned a Brandweek Marketer of the Year award for creating and promoting a portfolio of licensed celebrity and athlete brands for apparel retailer Steve & Barry’s. Earlier in his career, he led the communications department for SFX/Clear Channel Entertainment (subsequently rebranded as Live Nation).

Mr. Schacter received a Bachelor of Science degree from the University of Maryland at College Park.

Important Caution Regarding Forward-Looking Statements

This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events, including estimates and projections of revenue and EBITDA and about its business based on certain assumptions of its management, including those described in this release. These statements are not guaranteeing of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional risk factors are included in the Company’s public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “planned, “estimated,” “preparing,” “potential,” “expected,” “looks” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

(This information is primarily sourced from MariMed.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Financial Result, CBD Skin Care Market, Cannabis Testing Market

Global Cannabis Testing Market Analysis Report 2023-2030

February 4th, 2023|

DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...